Additional Information

Description

Truxima (rituximab-abbs) injection, solution 500 mg/50 mL (10 mg/mL), is a biosimilar monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is indicated for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). By selectively depleting CD20-positive B cells, Truxima reduces malignant cell proliferation in hematologic cancers and modulates immune responses in autoimmune diseases.

The mechanism of action involves binding to CD20 antigens on B-cell surfaces, leading to cell destruction through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. This targeted B-cell depletion reduces disease progression in NHL and CLL while decreasing inflammation in autoimmune disorders.

Infusion-related reactions, including fever, chills, hypotension, and respiratory distress, are common, particularly during the initial infusion. Premedication with antihistamines, corticosteroids, and acetaminophen is recommended to reduce these effects. Severe adverse reactions include progressive multifocal leukoencephalopathy (PML), severe infections, tumor lysis syndrome, and cardiac complications.